In conclusion, our comparative analysis of seven anti‐CD19 CAR designs using UCB‐derived NK cells indicates that the first‐generation CAR construct with CD8 TMD‐CD3ζ SD offers optimal anti‐tumour efficacy. Here, CD8A is linked to neoplasm.